Martek Biosciences Corporation

Twist Bioscience to Present at 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, December 18, 2023
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, Clinical Trials, Twist Bioscience, Silicon, Martek Biosciences Corporation, Conference, Doctor of Philosophy, Cryptocurrency, Self storage

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8 at 5:15 p.m. Pacific Time in San Francisco, CA.

Key Points: 
  • Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8 at 5:15 p.m. Pacific Time in San Francisco, CA.
  • The presentation will be webcast live and can be accessed by visiting the “Investor Calendar” page of the investor relations section of the company's website here .
  • A replay of the presentation will be archived for a period of 30 days following the conclusion of the live events.

Twist Bioscience Reports Fiscal Fourth Quarter and Full Year Fiscal 2023 Financial Results

Retrieved on: 
Friday, November 17, 2023
Biotechnology, Technology, Health, General Health, Pharmaceutical, Oncology, Health Technology, Research, Nanotechnology, Genetics, Science, Carbon, WGS, Twist Bioscience, Telephone, Gene, Twist, SynBio, Investment, Tax, Administration, Martek Biosciences Corporation, PIN, Doctor of Philosophy, Sutro Biopharma, Bayer, Development, Antibody, Growth, NGS, Silicon, ESG, Management, Tobacco, Spice, Video game, Pharmaceutical industry, Agriculture, Vaccine, Library

Revenue: Total revenues for fiscal 2023 grew to $245.1 million compared to $203.6 million for fiscal 2022.

Key Points: 
  • Revenue: Total revenues for fiscal 2023 grew to $245.1 million compared to $203.6 million for fiscal 2022.
  • Cost of Revenues: Cost of revenues for fiscal 2023 grew to $155.4 million compared to $119.3 million for fiscal 2022.
  • Orders: Total orders received for the fourth quarter of fiscal 2023 grew to $71.1 million compared to $62.1 million for the same period of fiscal 2022.
  • Revenue: Total revenues for the fourth quarter of fiscal 2023 grew to $66.9 million compared to $57.3 million for the same period of fiscal 2022.

Twist Bioscience Launches Express Genes Rapid Gene Synthesis Service

Retrieved on: 
Tuesday, November 14, 2023
Science, Biotechnology, Nanotechnology, Research, General Health, Health, Technology, Genetics, Carbon, Twist Bioscience, DNA, Therapy, Gene, Martek Biosciences Corporation, Doctor of Philosophy, Software, RNA, NGS, Silicon, ESG, Fine chemical, Vaccine, Twist

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of Twist Express Genes , a new leading gene synthesis service with an order to shipping turnaround time of five to seven business days.1

Key Points: 
  • Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of Twist Express Genes , a new leading gene synthesis service with an order to shipping turnaround time of five to seven business days.1
    “Twist Express Genes is our first new offering enabled by the increased capacity and streamlined processes in our Wilsonville facility.
  • We offer the rapid turnaround that our customers need in multiple formats and at the same speed for one or thousands of genes.
  • Due to scale enabled by Twist’s platform, orders of any size both small and large can be filled, and as with standard speed Twist Clonal Genes, Twist Express Genes are NGS sequence-verified as one hundred percent accurate.
  • Twist Express Genes can be cloned into catalog vectors or custom vectors so that customers can move right to experimentation.

Twist Bioscience to Present at 6th Annual Evercore ISI HealthCONx Conference

Retrieved on: 
Monday, November 13, 2023
Other Health, Research, Pharmaceutical, Technology, Semiconductor, Genetics, Science, Nanotechnology, Biotechnology, Other Technology, Other Science, Health, Twist Bioscience, Silicon, Martek Biosciences Corporation, Conference, Doctor of Philosophy, CFO, Cryptocurrency, Online shopping

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Jim Thorburn, CFO of Twist Bioscience, will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28 at 7:30 a.m. Eastern Time in Miami, FL.

Key Points: 
  • Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Jim Thorburn, CFO of Twist Bioscience, will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28 at 7:30 a.m. Eastern Time in Miami, FL.
  • The fireside chat will be webcast live and can be accessed by visiting the “Investor Calendar” page of the investor relations section of the company's website here .
  • A replay of the fireside chat will be archived for a period of 30 days following the conclusion of the live events.

Twist Bioscience to Report Fiscal 2023 Fourth Quarter and Full Year Financial Results on Friday, November 17, 2023

Retrieved on: 
Thursday, November 2, 2023
Science, Biotechnology, Nanotechnology, Research, Pharmaceutical, Health, Technology, Genetics, Martek Biosciences Corporation, Telephone, PIN, Silicon, Cryptocurrency, Auction, Security (finance)

The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to discuss its financial results and provide an update on the company’s business.

Key Points: 
  • The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to discuss its financial results and provide an update on the company’s business.
  • The press release with the financial results will be accessible from the company’s website prior to the conference call through the Investor Relations section under the “Company” tab at www.twistbioscience.com .
  • The conference call will be webcast live through the Investor Relations section under the “Company” tab at www.twistbioscience.com .
  • Those parties interested in participating via telephone must register on the Company’s Investor Relations website or by clicking here .

Twist Bioscience Launches Full Length Unique Dual Index Adapters to Enable PCR-free Whole Genome Sequencing

Retrieved on: 
Tuesday, October 31, 2023
Health, Technology, Nanotechnology, Genetics, Research, Science, Biotechnology, Martek Biosciences Corporation, Data analysis, RNA, UDI, PCR, Poster, Society, Genome, NGS, Abraxis BioScience, RNA-Seq, WGS, Artifact, Silicon, Enrichment, Doctor of Philosophy, Exome, Twist, Twist Bioscience, Rope, Nightclub

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of Twist Full Length Unique Dual Index Adapters to enable PCR-free whole genome sequencing (WGS) and multiplexing at scale.

Key Points: 
  • Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of Twist Full Length Unique Dual Index Adapters to enable PCR-free whole genome sequencing (WGS) and multiplexing at scale.
  • “With Twist Full Length UDI Adapters, we can enable PCR-free whole genome sequencing for our customers pursuing that approach, including our customers in Europe where PCR-free WGS has gained traction.”
    Twist Full Length UDI Adapters add to Twist’s portfolio of universal adapter systems, which include Twist Universal Adapter System and Twist High Throughput Universal Adapter System.
  • Twist Full Length UDI Adapters include 1,536 indexes and come in automation-friendly configurations of 96 or 384 sets of adapters, giving customers the ability to multiplex anywhere between two and 1,536 samples.
  • The full length UDI adapters can be used in various NGS workflows and for PCR-free whole genome sequencing.

Acurex Biosciences to Present at the Michael J. Fox Foundation Parkinson’s Disease Therapeutics Conference

Retrieved on: 
Tuesday, October 10, 2023
Health, Neurology, Research, Pharmaceutical, Science, Biotechnology, The Michael J. Fox Foundation, PD, Therapy, Martek Biosciences Corporation, MJFF, Parkinson's disease, Drug development, Conference, Disease, Parkinson, Fine chemical, Pharmaceutical industry

Acurex Biosciences Corporation, a privately-held biopharmaceutical company with a mission to stop neurodegeneration before it starts, has been selected to present at the 15th annual Parkinson’s Disease Therapeutics Conference hosted by the Michael J.

Key Points: 
  • Acurex Biosciences Corporation, a privately-held biopharmaceutical company with a mission to stop neurodegeneration before it starts, has been selected to present at the 15th annual Parkinson’s Disease Therapeutics Conference hosted by the Michael J.
  • The Parkinson's Disease Therapeutics Conference is the Michael J.
  • Fox Foundation's annual scientific conference and the only one in the world focused exclusively on Parkinson's disease drug development.
  • Each year, the PD Therapeutics Conference brings together 300 research and business development professionals from academia and industry, showcasing the most exciting and innovative research from MJFF's research portfolio.

Twist Bioscience Enters into Antibody Discovery and Licensing Option Agreement with Bayer of up to $188 Million

Retrieved on: 
Thursday, October 5, 2023
Technology, Biotechnology, Nanotechnology, Chemicals, Plastics, Health, Manufacturing, Pharmaceutical, Other Science, Research, Agriculture, Genetics, Natural Resources, Science, Clinical Trials, Partnership, Silicon, Antibody, Twist, Bayer, Twist Bioscience, Doctor of Philosophy, Phoenix Carnegie Library and Library Park, Exercise, Martek Biosciences Corporation, Patient, Pharmaceutical industry, Library

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced an antibody discovery, option and license agreement with Bayer.

Key Points: 
  • Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced an antibody discovery, option and license agreement with Bayer.
  • Under the terms of the agreement, Twist Biopharma Solutions, a division of Twist Bioscience, will leverage its Library of Libraries to conduct antibody discovery campaigns against targets to be determined by Bayer.
  • “Our ongoing partnership with Bayer leverages the full suite of our Twist Biopharma Solutions offering of antibody discovery services to identify the best antibodies for Bayer’s specific targets,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.
  • In total, Twist is eligible to receive up to $188 million in clinical and commercial milestone payments plus royalties.

Twist Bioscience Appoints Mark Buck as Senior Vice President, Operations

Retrieved on: 
Tuesday, October 3, 2023
Biotechnology, Technology, Health, General Health, Pharmaceutical, Oncology, Research, Nanotechnology, Genetics, Science, Clinical Trials, Apple Inc., Marine Corps Expeditionary Medal, Solectron, Celer (group), University, Twist Bioscience, Doctor of Philosophy, Martek Biosciences Corporation, Organization of the United States Marine Corps, National university, MBA, Twist, University of Illinois Urbana-Champaign, Growth, Silicon, Champaign–Urbana metropolitan area, Management

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Mark Buck as senior vice president, operations.

Key Points: 
  • Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Mark Buck as senior vice president, operations.
  • Mr. Buck brings experience improving manufacturing efficiency and driving revenue and margin through managing supply chain and operations, including planning, quality, procurement and logistics.
  • I look forward to drawing on my experience enhancing efficiency and productivity by integrating teams and processes to drive toward profitability,” said Mr. Buck.
  • He previously held leadership positions including vice president operations, global manufacturing, supply chain and logistics at Celerity Group; director, operations management at Solectron corporation; and senior supply chain operations manager at Apple Computer, Inc. Before joining industry, Mr. Buck served in the United States Marine Corps.

Twist Bioscience and IMIDomics Collaborate to Discover Antibodies for Applications in Immune-Mediated Inflammatory Diseases

Retrieved on: 
Wednesday, September 27, 2023
Research, Technology, Genetics, Public Relations, Investor Relations, Communications, Nanotechnology, Biotechnology, Health, Science, Other Science, Twist Bioscience, Doctor of Philosophy, Martek Biosciences Corporation, Multimedia, Phoenix Carnegie Library and Library Park, Antibody, Immunotherapy, Patient, Biobank, Immune-mediated inflammatory diseases, Drug discovery, Silicon, Vaccine, Library

View the full release here: https://www.businesswire.com/news/home/20230927418930/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230927418930/en/
    The targets were identified using IMIDomics’ proprietary Clinical Discovery Engine™, a multidimensional, integrated, and data-driven platform for uncovering the underlying mechanisms of IMIDs.
  • IMIDomics will receive human antibodies against several of its priority targets from Twist.
  • “We leverage our proprietary Clinical Discovery Engine™ to interrogate multiple layers of biological information to identify targets not previously associated with immune-mediated inflammatory diseases.
  • We are already at work using the discoveries we've made to date to develop and validate a robust pipeline of drug candidates for these diseases.